🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥
Login

News on Medial

Related News

Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group

EntrackrEntrackr · 4d ago
Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group
Medial

Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group Lamark's proprietary ProteoStrong platform enables the stabilization of fragile protein-based drugs, such as insulin, monoclonal antibodies, and enzymes, without altering their molecular structure. Biopharma startup Lamark Biotech has raised Rs 6.5 crore in a pre-Series A round led by IAN Group, including IAN Alpha Fund, powered by BioAngels, Vinayender Tulla, Nita Roy, and Venkataraman KNK. Domain experts from IAN’s angel investors led the round. The Ahmedabad-based company had previously raised $41.3K in a seed funding round led by VIT-TBI and others. The fresh funds will be utilized to accelerate the development of thermostable insulin and expand the biologics platform for global access, Lamark said in a press release. Founded in 2018 by Vaibhav Bhatia, Lamark Biotech aims to reimagine drug delivery for chronic and life-altering diseases. Its proprietary ProteoStrong platform enables the stabilization of fragile protein-based drugs, such as insulin, monoclonal antibodies, and enzymes, without altering their molecular structure. According to Lamark Biotech, it leverages the R&D base of Venture Center, NCL Innovation, and it is advancing a new class of temperature-resilient biologics that retain potency across extreme conditions—ideal for underserved regions where cold storage infrastructure is limited. With its lead program, InsulinStrong, Lamark is targeting the Rs 4,000 crore Indian insulin market and intends to expand across Southeast Asia and the UAE. In the next 24 months, it plans to file new international patents, begin early clinical trials, and build partnerships with pharma companies, CDMOs, and global health agencies.

Exclusive: SolarSquare raises fresh funds from Zerodha's Rainmatter, Gruhas, others

EntrackrEntrackr · 1y ago
Exclusive: SolarSquare raises fresh funds from Zerodha's Rainmatter, Gruhas, others
Medial

Rooftop solar startup SolarSquare has raised $4.2 million from existing investors Zerodha’s Rainmatter Capital, Abhijeet Pai and Nikhil Kamath’s Gruhas Proptech, Lowercrabon Capital, Climate Angels and Good Capital. The board at SolarSquare has passed a special resolution to allot 7,589 Series B compulsory convertible debentures at an issue price of Rs 46,710 to raise Rs 35.44 crore, its regulatory filing shows. Lowercarbon and Good Capital invested Rs 20.74 crore and 3.32 crore while Gruhas Proptech and Rainmatter separately pumped in Rs 6.22 crore and Rs 3.98 crore, respectively. The funding will be used for the expansion, working capital requirements, and general corporate purposes, according to the filings. Every debenture issue during the round will be converted into a preference share at the next qualified funding round and the investors are considering the same to take place at a valuation of $75 million, the filings further added. As per TheKredible estimates, the company has been valued at around Rs 394 crore or $48 million post-allotment. The company is likely to raise more funds in this round and the valuation may vary after the final tranche. SolarSquare has raised over $20 million to date including its Rs 100 crore ($12 million) Series A round led by Elevation Capital and Lowercarbon in November 2022. According to the startup data intelligence platform TheKredible, Lowercrabon is the largest external stakeholder with 20.29% followed by Elevation Capital which holds 14.99%. Rainmatter and Gruhas Proptech own 3.84% and 2.50% respectively in SolarSquare. Head to TheKredible for the complete shareholding pattern. Founded by Neeraj Jain and Nikhil Nahar, SolarSquare designs, installs, and finances rooftop solar systems for homes. It also provides rooftop solar solutions for housing societies and commercial establishments. The company is yet to file its financial statements for FY24 but its revenue from operations grew 35.4% to Rs 107 crore in FY23. It posted Rs 35 crore loss in the same period. SolarSquare competes with Zunroof, Cleantech, Mysun, Oorjan, and Freyr Energy, among others. In February, the company acquired PV Diagnostics, a company with expertise in the utility scale solar power sector. Update: The story and headline have been updated to reflect Zerodha Technology as Zerodha’s Rainmatter Capital.

Allo Health raises Rs 16 Cr in pre-Series A round

EntrackrEntrackr · 3m ago
Allo Health raises Rs 16 Cr in pre-Series A round
Medial

Allo Health raises Rs 16 Cr in pre-Series A round Sexual health startup Allo Health has raised Rs 16 crore ($1.83 million) in its pre-Series A round led by Rainmatter along with existing investors. Prior to this round, Allo had raised $4.4 million in seed funding led by Nexus Venture Partners, with participation from founders and operators, including Binny Bansal (Flipkart), Deepinder Goyal (Zomato), Rohit MA (Cloudnine), and Sandeep Singhal (Nexus). The proceeds will be used to ramp up clinic densification, invest in deeper technology capabilities, and enhance patient engagement as Allo continues to scale. Founded by Pranay Jivrajka, Allo has built a hybrid ecosystem that combines physical clinics, AI-powered treatment protocols, and trained medical professionals. Allo’s proprietary doctor training programs, AI-powered clinical decision support, and research-backed treatment helps it manage effectively. Since its inception, Allo claims to have treated over 200,000 patients across India, achieving a 85% improvement in patient outcomes, with over 35 clinics across major cities, including Bangalore, Mumbai, Pune, Hyderabad, Chennai, Mysore, and Ranchi.

The Bear House raises Rs 50 Cr in Series A round led by JM Financial

EntrackrEntrackr · 3m ago
The Bear House raises Rs 50 Cr in Series A round led by JM Financial
Medial

The Bear House raises Rs 50 Cr in Series A round led by JM Financial The Bear House, a popular men’s fashion brand, has raised Rs 50 crore ($5.84 million) in its Series A round led by JM Financial India Growth Fund III. The proceeds will be used to open more physical stores, boost branding efforts, and meet working capital needs. The Bear House sells products like shirts, t-shirts, jeans, and footwear. It has mainly been sold online through platforms like Myntra, Flipkart, and Nykaa. Led by Harsh Somaiya, the firm opened its first physical store in Bengaluru in March 2025. It now plans to launch 20 more stores across India in the next two years. The Bengaluru-based startup claims to have already built a Rs 150 crore online brand while staying profitable and self-funded until now.

Exclusive: Even Healthcare raises $20 Mn led by Khosla Venture

EntrackrEntrackr · 10m ago
Exclusive: Even Healthcare raises $20 Mn led by Khosla Venture
Medial

Healthcare company Even Healthcare has raised Rs 169 crore (approximately $20 million) in a new round led by Khosla Ventures. The fresh funding for the Bengaluru-based firm has come after a gap of 20 months. The board at Even has passed a resolution to issue 2,17,589 preference shares at an issue price of Rs 7,762 each to raise Rs 169 crore or $20 million, its filing sourced from the Registrar of Companies shows. Khosla Ventures led the round with Rs 83.4 crore or $10 million while Pathfinder and Mercury Fund invested Rs 21.3 crore and 26.9 crore, respectively. Simon Fiduciaria, DLB Ventures, Lex Italia, 8 VC, Rainmatter fintech, and others cumulatively injected the rest amount. Even Healthcare has also expanded its employee stock option (ESOP) pool, adding new options that bring the total pool size to 1,35,000, according to a separate resolution filed by the company. According to Entrackr’s estimates, its ESOP size is worth $12 million. As per startup data intelligence platform TheKredible, the company has been valued at around Rs 753 crore or $91 million post-allotment. Even offers subscription-based plans to cover diagnostics, consultations, and hospitalization costs of up to Rs 50 lakh. According to the company, it only partners with those hospitals that guarantee the care of its members in exchange for a recurring payment. Launched by Mayank Banerjee, Matilde Giglio and Alessandro Lalongo, Even also offers personalized managed care programs and provides Even cards which can be used to pay bills at its partner hospitals and labs. Even claims to have an advantage over medical insurance as it provides unlimited OPD consultations and diagnostics. The company has raised approximately $40 million to date, including $15 million from Alpha Wave and Aspada in November 2022, and an initial $5 million in seed capital led by Khosla Ventures in 2021. Entrackr exclusively reported about its seed funding in July 2021.

Exclusive: Kiran Mazumdar Shaw’s Immuneel Therapeutics raises Rs 100 Cr

EntrackrEntrackr · 12m ago
Exclusive: Kiran Mazumdar Shaw’s Immuneel Therapeutics raises Rs 100 Cr
Medial

Cancer focused biotech startup Immuneel Therapeutics has raised Rs 100 crore or $12 million in the extension of Series A round from Taiba Middle East FZ LLC. This is the third round of investment for the Bengaluru-based company since its inception in 2018. The board at Immuneel Therapeutic has passed a special resolution to issue 1o equity shares and 8,164 Series A1 CCPS at an issue price of Rs 1,22,330 each to raise Rs 100 crore or $12 million, its regulatory filing accessed from the Registrar of Companies show. The company will use these investments for growth and expansion as decided by the board, the filings further added. As per TheKredible’s estimates, the firm has been valued at around Rs 587 crore or $71 million (post-allotment). Following the fresh proceeds, Taiba Middle East FZ holds a 17% stake in Immuneel Therapeutics. The round appears to be ongoing and it may raise more funds. The company has raised around $40 million to date including its $15 million Series A financing co-led by Eight Roads Ventures, True North, and F-Prime Capital in 2022. Founded by Biocon founder Kiran Mazumdar Shaw, oncologist and Pulitzer winner — Siddhartha Mukherjee and Kush Parwar, Immuneel Therapeutics is an Indian clinical-stage startup which is engaged in developing cell and gene therapies for cancer patients. It’s also working on developing its own pipeline of chimeric antigen receptor T-cell (CAR-T) therapies and other cellular immunotherapies for management and treatment of cancer. The firm claims to offer therapies at one-third of the costs borne for gene therapies in America. While the company is yet to file its annual statements for FY24, six-year-old Immuneel Therapeutics remained at a pre-revenue stage in FY23. Its losses stood at Rs 39 crore in the fiscal year ending March 2023.

Download the medial app to read full posts, comements and news.